Exscientia–Evercore: investor conference, 202311 supply service Exscientia participates in Evercore ISI HealthCONx Conference 2023

	Period	2023-11-28
	Predecessor	Exscientia–Evercore: investor conference, 202211 supply service Exscientia participates in Evercore ISI HealthCONx Conference 2022
	Partner, 1st	Exscientia plc (Nasdaq: EXAI)
	Group	Exscientia (Group)
	Partner, 2nd	Evercore ISI
	Group	Evercore (Group)
	Product	Evercore ISI HealthCONx Conference 2022 DIGITAL
	Product 2	AI-based drug discovery / AI-based drug development

Exscientia plc. (11/21/23). "Press Release: Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference". Oxford.

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at www.exscientia.ai or follow us on X/Twitter @exscientiaAI.

Investor Relations:
Sara Sherman
investors@exscientia.ai

Media:
Oliver Stohlmann
media@exscientia.ai
Source: Exscientia plc